The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: study design, aminoglycosides dosing and technique of nebulisation

Jean-Jacques Rouby (1) , Antoine Monsel (2) , Marc Leone (3, 4) , Olivier Mimoz (5, 6) , Pierre-François Laterre (7) , Jerôme Pugin (8)

1 CHU Pitié-Salpêtrière [AP-HP]
2 I3 - Immunologie - Immunopathologie - Immunothérapie
3 MEPHI - Microbes évolution phylogénie et infections
4 Service Anesthésie et Réanimation [Hôpital Nord - APHM]
5 Service d'anesthésie réanimation [Poitiers]
6 PHAR - Pharmacologie des anti-infectieux
7 Intensive Care Unit
8 Intensive Care Medicine Unit

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Bacteriology; Life Sciences [q-bio]; Microbiology and Parasitology; Virology; Life Sciences [q-bio]; Microbiology and Parasitology; Parasitology; Life Sciences [q-bio]; Human health and pathology; Cardiology and cardiovascular system; Life Sciences [q-bio]; Human health and pathology; Emerging diseases; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

Jean-Jacques Rouby, Antoine Monsel, Marc Leone, Olivier Mimoz, Pierre-François Laterre, et al.. The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: study design, aminoglycosides dosing and technique of nebulisation. Anaesthesia Critical Care & Pain Medicine, 2020, ⟨10.1016/j.accpm.2020.03.007⟩. ⟨hal-02509371⟩